ReviewNature reviews. Endocrinology2024
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
Open access · bronzeAbstract readReviewConsensus Statement
In one paragraph
Review in Nature reviews. Endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
25.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.Endocrine journal · 2026Guideline
- Revisiting radioresistance: a systematic review of outcomes of Stereotactic radiosurgery (SRS) in functional head and neck paragangliomas.Neurosurgical review · 2025Pooled it
- Phase II Study ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- Sweet syndrome with reactive lymphadenopathy mimicking metastatic disease in anJCEM case reports · 2026Article
- Unbiased CRISPR synthetic lethal screening for genetic vulnerabilities in a succinate dehydrogenase-loss model of paraganglioma.iScience · 2026Article
- Article
- Toward personalized management of metastatic PPGL: decoding the implications of theInternational journal of surgery (London, England) · 2026Article
- Pheochromocytomas and Paragangliomas.Endocrinology and metabolism clinics of North America · 2026Review
- Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells.Endocrine-related cancer · 2026Article
- Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas.Molecular biomedicine · 2026Article
- A rare case of giant paraganglioma in the first porta hepatis area associated with neurofibromatosis type 1.Hepatobiliary surgery and nutrition · 2026Article
- Mapping the neglected topic in head and neck paraganglioma research: a PRISMA scoping review on quality of life.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.Endocrine-related cancer · 2026Article
- Bilateral pheochromocytoma: case series and review of treatment strategies based on genetic mutations.Translational andrology and urology · 2026Article
- Functional characterization of SDHB variants: Advancing succinate dehydrogenase biology and variant curation in hereditary paraganglioma.The Journal of clinical investigation · 2026Article
- Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Insights into imaging · 2026Article
- Clinical and Genetic Characteristics of Pheochromocytoma and Paraganglioma: A Single-Center Experience Including a Rare VHL Variant.Journal of clinical medicine · 2026Article
- Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 14 countries.
David TaïebDepartment of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital, Marseille, France.
Svenja NöltingDepartment of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Nancy D PerrierDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Martin FassnachtDepartment of Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0001-6170-6398
Jorge A CarrasquilloMolecular Imaging and Therapy Service, Radiology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8513-5734
Ashley B GrossmanGreen Templeton College, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1176-6186
Roderick Clifton-BlighDepartment of Endocrinology, Royal North Shore Hospital and Cancer Genetics Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-1545-0368
George B WannaDepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zachary G SchwamDepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Laurence AmarUniversité Paris Cité, Inserm, PARCC, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID http://orcid.org/0000-0003-3942-4276
Isabelle BourdeauDivision of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.
Ruth T CaseyDepartment of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Joakim CronaDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-0677-4894
Cheri L DealResearch Center, CHU Sainte-Justine and Dept. of Paediatrics, University of Montreal, Montreal, Québec, Canada.ORCID http://orcid.org/0000-0001-6434-2745
Jaydira Del RiveroDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Quan-Yang DuhDepartment of Surgery, UCSF-Mount Zion, San Francisco, CA, USA.
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany.
Tito FojoColumbia University Irving Medical Center, New York City, NY, USA.
Hans K GhayeeDivision of Endocrinology & Metabolism, Department of Medicine, University of Florida, Gainesville, FL, USA.
Anne-Paule Gimenez-RoqueploUniversité Paris Cité, Inserm, PARCC, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID http://orcid.org/0000-0002-4816-670X
Antony J GillUniversity of Sydney, Sydney NSW Australia, Cancer Diagnosis and Pathology Group Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Rodney HicksDepartment of Medicine, St Vincent's Hospital Medical School, Melbourne, Victoria, Australia.
Alessio ImperialeDepartment of Nuclear Medicine and Molecular Imaging - Institut de Cancérologie de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS, University of Strasbourg, Strasbourg, France.
Abhishek JhaSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1489-2471
Michiel N KerstensDepartment of Endocrinology, University Medical Center Groningen, Groningen, Netherlands.
Ronald R de KrijgerDepartment of Pathology, University Medical Center Utrecht, Utrecht, Netherlands.
André LacroixDivision of Endocrinology, Department of Medicine, Centre de recherche du Centre hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Canada.ORCID http://orcid.org/0000-0003-4137-3025
Ivica LazurovaDepartment of Internal Medicine 1, University Hospital, P.J. Šafárik University, Košice, Slovakia.
Frank I LinMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Charlotte Lussey-LepoutreUniversité Paris Cité, Inserm, PARCC, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID http://orcid.org/0000-0003-2228-0106
Eamonn R MaherDepartment of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-6226-6918
Ozgur MeteDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Mitsuhide NaruseClinical Research Institute of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center and Endocrine Center, Kyoto, Japan.
Naris NilubolSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mercedes RobledoHereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0001-6256-5902
Frédéric SebagDepartment of Endocrine Surgery, Aix-Marseille University, Conception Hospital, Marseille, France.
Nalini S ShahDepartment of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Akiyo TanabeDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5682-4952
Geoffrey B ThompsonDivision of Endocrine Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Henri J L M TimmersDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Jiri WidimskyThird Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
William J YoungDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
Leah MeuterStanford University School of Medicine, Department of Physician Assistant Studies, Stanford, CA, USA.
Jacques W M LendersDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID http://orcid.org/0000-0002-7658-4466
Karel PacakSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. karel@mail.nih.gov.ORCID http://orcid.org/0000-0002-3541-3767
National Institutes of Health · USInserm · FRAix-Marseille Université · FRCentre Hospitalier de l’Université de Montréal · CAIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USRadboud University Nijmegen · NLRoyal North Shore Hospital · AUUniversity of Cambridge · GBCentre Hospitalier Universitaire Sainte-Justine · CACentre National de la Recherche Scientifique · FRCharles University · CZColumbia University Irving Medical Center · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USInstituto de Salud Carlos III · ESKing Edward Memorial Hospital and Seth G.S. Medical College · INKyoto Medical Center · JPMemorial Sloan Kettering Cancer Center · USNational Center for Global Health and Medicine · JPStanford Medicine · US
Funding
Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and ParagangliomaZIAHD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2009 to 2024
$28.4MSurgical Oncology Program Training ProgramZIEBC012097 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BLAKELY, ANDREW · 2022 to 2025
$17.3MAbstract
Adult and paediatric patients with pathogenic variants in the gene encoding succinate dehydrogenase (SDH) subunit B (SDHB) often have locally aggressive, recurrent or metastatic phaeochromocytomas and paragangliomas (PPGLs). Furthermore, SDHB PPGLs have the highest rates of disease-specific morbidity and mortality compared with other hereditary PPGLs. PPGLs with SDHB pathogenic variants are often less differentiated and do not produce substantial amounts of catecholamines (in some patients, they produce only dopamine) compared with other hereditary subtypes, which enables these tumours to grow subclinically for a long time. In addition, SDHB pathogenic variants support tumour growth through high levels of the oncometabolite succinate and other mechanisms related to cancer initiation and progression. As a result, pseudohypoxia and upregulation of genes related to the hypoxia signalling pathway occur, promoting the growth, migration, invasiveness and metastasis of cancer cells. These factors, along with a high rate of metastasis, support early surgical intervention and total resection of PPGLs, regardless of the tumour size. The treatment of metastases is challenging and relies on either local or systemic therapies, or sometimes both. This Consensus statement should help guide clinicians in the diagnosis and management of patients with SDHB PPGLs.
Indexed as
Adrenal Gland NeoplasmsParagangliomaPheochromocytomaAdultChildGerm-Line MutationHumansSuccinate DehydrogenaseSDHB protein, humanSuccinate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.